Panbela Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.panbela.com
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Panbela Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05254171
- Locations
- 🇬🇧
Derriford Hospital, Plympton, Devon, United Kingdom
🇧🇪CHU UCL Namur asbl - Site Godinne, Yvoir, Namur, Belgium
🇧🇪Onze-Lieve-Vrouwziekenhuis, Aalst, Oost-Vlaanderen, Belgium
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Panbela Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03412799
- Locations
- 🇦🇺
Blacktown Cancer & Haematology Centre, Blacktown, New South Wales, Australia
🇺🇸Scripps MD Anderson Cancer Center, La Jolla, California, United States
🇦🇺Ashford Cancer Centre, Kurralta Park, South Australia, Australia
Study of SBP-101 in Pancreatic Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- Panbela Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02657330
- Locations
- 🇦🇺
Ashford Cancer Centre, Kurralta Park, South Australia, Australia
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
© Copyright 2024. All Rights Reserved by MedPath